Glenmark Life Sciences reports revenue growth of 32 2% and PAT growth of 24 5% YoY for Q1 FY22
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Glenmark Pharmaceuticals Ltd s stake in Glenmark Life Sciences Limited reduces to 82 84% post IPO
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Anatara Lifesciences Limited (ASX:ANR) Monthly Activities Report
Monthly Activities ReportMelbourne, July 28, 2021 AEST (ABN Newswire) - Anatara Lifesciences Limited (
ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have made solid progress in obtaining the appropriate approval and grants for our human and animal health products over this period. We are at an exciting phase of Anatara s development, with two human clinical trials now imminent, and a number of pathways being pursued for the commercialisation of both the human and animal products.
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara s human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.Read Full Article▸
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).Read Full Article▸